BLINCYTO 35/38.5 mcg

Note: – Blincyto is an FDA approved drug.

• Assess patients with blinatumomab injection for signs and symptoms of neurological toxicities. Advise outpatients on Blinatumomab to contact their health specialist if they develop signs/symptoms of neurological toxicities.
• Monitor patients with Blincyto doses for signs and symptoms of infection and treat appropriately.
• Assess laboratory parameters (including, but not limited to, WBC count and absolute neutrophil count) during blinatumomab infusion. Interrupt this medication if prolonged neutropenia occurs.
• Monitor aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), and total blood bilirubin before the start of and while on Blincyto 35 mcg treatment.
• Assess patients who develop signs of pancreatitis. Management of pancreatitis may need either temporary interruption or discontinuation of Blincyto injection and dexamethasone. 
• Healthcare professionals recommend not to have vaccination with live virus vaccines for at least before 2 weeks Blinatumomab 35 mcg treatment, during treatment, and until immune recovery following the last cycle of Blinatumomab.

Blincyto is the trade name for the drug Blinatumomab.

Is Blincyto® approved by the FDA?

Yes, Blincyto® is approved by the FDA. Date of approval: 2014.

lincyto is a prescription only medicine, which is used in treating patients with B-cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease greater than or equal 0.1% and relapsed or refractory B-cell precursor ALL (Acute Lymphoblastic Leukemia).

Blincyto® is available as 35 mcg of lyophilized powder in a single-use vial for reconstitution.

The active ingredient in the vials is Blinatumomab with inactive ingredients citric acid monohydrate, lysine hydrochloride, polysorbate 80, trehalose dihydrate, sodium hydroxide preservative-free sterile water for injection.

Blincyto is an immunotherapy medicine because it works with the immune system to find and destroy cancer cells. The drug Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 expressed on the surface of cells of B-lineage origin, and CD3 expressed on the surface of T cells.

You can call or WhatsApp +91-9310090915 or email info@indianpharmanetwork.in to know the Blincyto cost.

On June 14, 2024, the FDA approved Blincyto for use in adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) during the consolidation phase of chemotherapy. This approval allows its use regardless of measurable residual disease (MRD) status, expanding its applicability to more patients.

Clinical trials have shown that Blincyto, when added to a multiphase consolidation chemotherapy regimen, significantly improves overall survival rates compared to chemotherapy alone. In the E1910 study, the three-year overall survival was 84.8% for patients receiving Blincyto plus chemotherapy, compared to 69% for those on chemotherapy alone. The five-year overall survival also showed a marked improvement, demonstrating Blincyto’s potential to enhance long-term outcomes.

Blincyto is the first and only bispecific T-cell engager (BiTE) therapy approved for the consolidation treatment of B-ALL, regardless of MRD status. This makes it a pioneering option in immuno-oncology, leveraging the body’s immune system to target and destroy cancer cells by bringing T-cells into proximity with cancerous B-cells.

Recent clinical trials, including the E1910 and 20120215 studies, have reaffirmed Blincyto’s efficacy in increasing overall survival and relapse-free survival rates in both adult and pediatric patients with B-ALL. These trials underline the significant impact of Blincyto on long-term patient outcomes, highlighting its role in the consolidation phase of chemotherapy.

Blincyto injection is available in Asian countries like Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka.

Indian Pharma Network (IPN) can facilitate the supply of Blincyto (prescription medicine) to locations worldwide while adhering to legal requirements.